BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1418 related articles for article (PubMed ID: 26626802)

  • 21. Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection.
    Li Y; Zhang R; Han Y; Lu T; Ding J; Zhang K; Lin G; Xie J; Li J
    Diagn Pathol; 2016 Sep; 11(1):85. PubMed ID: 27613595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.
    Gjerdrum LM; Sorensen BS; Kjeldsen E; Sorensen FB; Nexo E; Hamilton-Dutoit S
    J Mol Diagn; 2004 Feb; 6(1):42-51. PubMed ID: 14736826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Usefulness of a One-Tube Nested Reverse Transcription Quantitative Polymerase Chain Reaction Assay for Evaluating Human Epidermal Growth Factor Receptor 2 mRNA Overexpression in Formalin-Fixed and Paraffin-Embedded Breast Cancer Tissue Samples.
    Wang HY; Ahn S; Park S; Kim S; Lee H
    Pathobiology; 2017; 84(2):57-70. PubMed ID: 27544315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
    Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].
    Lee JW; Noh WC; Kim MS; Kim HA; Chang YH; Hong YJ; Hong SI; Lee JK
    Korean J Lab Med; 2008 Oct; 28(5):392-9. PubMed ID: 18971621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
    Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2 mRNA transcript quantitation in breast cancer.
    Meehan K; Clynick B; Mirzai B; Maslen P; Harvey JM; Erber WN
    Clin Transl Oncol; 2017 May; 19(5):606-615. PubMed ID: 27837339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
    Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
    Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis.
    Wang Y; Tsang JYS; Cui Y; Cui J; Lin Y; Zhao S; Law PTW; Cheung SY; Ng EKO; Tse GMK; Ke Z
    Sci Rep; 2017 Jul; 7(1):6752. PubMed ID: 28754904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiplexed tandem polymerase chain reaction identifies strong expression of oestrogen receptor and Her-2 from single, formalin-fixed, paraffin-embedded breast cancer sections.
    Thompson EW; Warton K; Blick T; Wafai R; Hill P; Stanley K
    Pathology; 2010 Feb; 42(2):165-72. PubMed ID: 20085519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers.
    Niu D; Li L; Yu Y; Zang W; Li Z; Zhou L; Jia L; Rao G; Gao L; Cheng G; Ji K; Lin D
    Pathol Oncol Res; 2020 Oct; 26(4):2577-2585. PubMed ID: 32621174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
    Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
    Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
    Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
    Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
    BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
    Ying JM; Liu XY; Guo L; Xie YQ; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.